- By FYH News Team
[ad_1]
doi: 10.1097/JXX.0000000000001108.
Online ahead of print.
Affiliations
Item in Clipboard
J Am Assoc Nurse Pract.
.
Abstract
Depression is a leading cause of disability worldwide, with treatment-resistant depression (TRD) affecting approximately 30% of patients who do not respond to standard antidepressants. In underserved and uninsured communities, where Nurse Practitioners (NPs) often provide essential mental health care, the challenges of managing TRD are compounded by limited access to specialized services. Pharmacogenomic testing offers a promising approach to overcoming these barriers by providing personalized medication recommendations based on a patient’s genetic profile. This brief report examines the medical records of 46 patients from underserved communities who underwent genetic testing for TRD. Of the patients reviewed, 31 achieved remission within 2 months of receiving genetically guided treatment, resulting in a remission rate of 67.39%. Patients with specific genetic markers, such as poor metabolizers for CYP2D6 or CYP2C19, experienced the most significant benefits. These findings suggest that pharmacogenomic testing can significantly improve treatment outcomes for TRD in underserved populations, enabling NPs to provide more personalized, effective care. Further research is necessary to explore the long-term benefits and cost-effectiveness of integrating pharmacogenomic testing into NP-led practices, particularly in resource-limited settings.
Copyright © 2024 American Association of Nurse Practitioners.
Conflict of interest statement
Competing interests: The authors report no conflicts of interest.
References
-
-
Baig-Ward K. M., Jha M. K., Trivedi M. H. (2023). The individual and societal burden of treatment-resistant depression: An overview. The Psychiatric Clinics of North America, 46(2), 211–226. https://doi.org/10.1016/j.psc.2023.02.001
–
DOI
-
-
-
Bousman C. A., Hopwood M. (2016). Commercial pharmacogenetic-based decision-support tools in psychiatry. The Lancet. Psychiatry, 3(6), 585–590. https://doi.org/10.1016/S2215-0366(16)00017-1
–
DOI
-
-
-
Cipriani A., Furukawa T. A., Salanti G., Chaimani A., Atkinson L. Z., Ogawa Y., Leucht S., Ruhe H. G., Turner E. H., Higgins J. P. T., Egger M., Takeshima N., Hayasaka Y., Imai H., Shinohara K., Tajika A., Ioannidis J. P. A., Geddes J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet (London, England), 391(10128), 1357–1366. https://doi.org/10.1016/S0140-6736(17)32802-7
–
DOI
-
-
-
Coombs N. C., Campbell D. G., Caringi J. (2022). A qualitative study of rural healthcare providers’ views of social, cultural, and programmatic barriers to healthcare access. BMC Health Services Research, 22(1), 438. https://doi.org/10.1186/s12913-022-07829-2
–
DOI
-
-
-
Fenton C., McLoughlin D. M. (2021). Usefulness of Hamilton rating scale for depression subset scales and full versions for electroconvulsive therapy. PloS One, 16(11), e0259861. https://doi.org/10.1371/journal.pone.0259861
–
DOI
-
[ad_2]
Source link
Trending Topics
Features
- Drive Toolkit
Download and distribute powerful vaccination QI resources for your community.
- Health Champions
Sign up now to support health equity and sustainable health outcomes in your community.
- Cancer Early Detection
MCED tests use a simple blood draw to screen for many kinds of cancer at once.
- PR
FYHN is a bridge connecting health information providers to BIPOC communities in a trusted environment.
- Medicare
Discover an honest look at our Medicare system.
- Alliance for Representative Clinical Trials
ARC was launched to create a network of community clinicians to diversify and bring clinical trials to communities of color and other communities that have been underrepresented.
- Reducing Patient Risk
The single most important purpose of our healthcare system is to reduce patient risk for an acute event.
- Victor Mejia
- Victor Mejia
